The Front Cover shows vilaprisan, a highly selective progesterone receptor modulator (SPRM), bound to the progesterone receptor (PR). Gynecologic diseases such as uterine fibroids and endometriosis depend on progesterone receptor function. Women affected by these diseases may suffer from heavy menstrual bleeding, pelvic pain, and/or infertility. Based on its high potency, high selectivity for the PR, and favorable pharmacokinetic properties, vilaprisan has the potential to offer a medical solution addressing the high unmet need in these indications. More information can be found in the Full Paper by Wolfgang Schwede et al. on page 2271 in Issue 21, 2018 (DOI: 10.1002/cmdc.201800487).

中文翻译：

---

封面：发现Vilaprisan（BAY 1002670）：一种针对妇科治疗进行了优化的高效，选择性强的孕激素受体调节剂（ChemMedChem 21/2018）

封面显示了vilaprisan，一种高度选择性的孕激素受体调节剂（SPRM），与孕激素受体（PR）结合。诸如子宫肌瘤和子宫内膜异位的妇科疾病取决于孕激素受体的功能。受这些疾病影响的女性可能会遭受严重的月经出血，骨盆疼痛和/或不孕症。基于其高效能，对PR的高选择性以及良好的药代动力学特性，紫杉醇具有提供可解决这些适应症未满足需求的医学解决方案的潜力。更多信息，请参见Wolfgang Schwede等人的《全文》。就在问题21，2018 2271页（：10.1002 / cmdc.201800487 DOI）。